Corporate ProfileWe are a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Oct 12, 2017AnaptysBio Announces Pricing of Public Offering
Oct 10, 2017AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis
There are currently no events scheduled.